- Quotient Sciences has extended its commercial supply partnership with Ipsen to manufacture Sohonos (Palovarotene), an FDA-approved treatment for Fibrodysplasia Ossificans Progressiva (FOP), a disease affecting fewer than 1,000 people worldwide.
- Ipsen has invested in new containment and handling equipment at Quotient’s Boothwyn, Pennsylvania facility to support highly potent API manufacturing.
Quotient Sciences has announced an extended commercial supply partnership with Ipsen to manufacture Sohonos (Palovarotene), a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 patients globally. Sohonos was approved by the FDA in 2023 and is classified as a highly potent molecule requiring specialized containment and handling.
The collaboration includes Ipsen’s investment in new equipment at Quotient Sciences’ Boothwyn, Pennsylvania facility. The additions include a Pneumatic Closed Transfer System for safe material transfer without impacting blend segregation and a Flexible Dispensing Isolator designed to enhance operator safety and eliminate special cleaning requirements. The upgrades expand the site’s ability to manage highly potent API (HPAPI) drug molecules with occupational exposure limits (OELs) at or below 1 µg/m³.
The partnership supports sustained commercial supply of the FOP therapy and broadens the site’s capabilities to manufacture multiple highly potent compounds at commercial scale. Quotient Sciences operates as an integrated CRDMO, providing contract research, development and manufacturing services, including global shipment management.
“By expanding our capabilities in handling highly potent compounds, we are not only ensuring a reliable supply of critical therapies like Sohonos (Palovarotene) for the FOP community, but also reinforcing our promise to deliver flexible, high-quality solutions for our partners with specialized needs especially for highly potent compounds.”
Marlene Leuenberger, VP and General Manager, Quotient Sciences, Philadelphia
